Mills Kenneth T. - 08 Nov 2021 Form 4 Insider Report for REGENXBIO Inc. (RGNX)

Role: President and CEO, Director
Signature: /s/ Patrick J. Christmas as attorney-in-fact
Issuer symbol: RGNX
Transactions as of: 08 Nov 2021
Net transactions value: -$54,360
Form type: 4
Filing time: 10 Nov 2021, 15:12:41 UTC
Previous filing: 29 Sep 2021
Next filing: 06 Dec 2021
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	RGNX	Common Stock	Options Exercise	$5,640	+1,500	+0.53%	$3.76^*	282,484	08 Nov 2021	Direct	F1
transaction	RGNX	Common Stock	Sale	$60,000	-1,500	-0.53%	$40.00	280,984	08 Nov 2021	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	RGNX	Employee Stock Option (Right to Buy)	Options Exercise	$0	-1,500	-0.65%	$0.000000	229,854	08 Nov 2021	Common Stock	1,500	$3.76	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	This transaction was effected pursuant to a Rule 10b5-1 trading plan.
F2	The previously granted option, representing a right to purchase a total of 275,000 shares, became exercisable as follows: 25% of the shares subject to this option vested on May 19, 2016, and the balance vested in equal monthly installments over the 36 months thereafter.